Antimicrobial Stewardship in COVID times: a challenge within a challenge
12 July 2021
12. COVID-19, 1,5-hour Symposium
12h. Infection control
•
2722
•
19:15
>
20:45
•
Antimicrobial Stewardship in COVID times: a challenge within a challenge
•
12. COVID-19
12h. Infection control
The SARS-CoV-2 pandemic is currently dominating every aspect of health care across the globe, putting other longer-term public health issues—including the steady rise of antimicrobial resistance—in the shade. Yet, there will be a time after COVID-19, and we should not lose sight of problems that will persist and may potentially be exacerbated by this pandemic. As much as 72% of patients admitted with COVID-19 receive antibiotics, many for inappropriate reasons. In this session we will discuss the relevance of concomitant bacterial and fungal (co)infections in COVID-19, the role that biomarkers such as procalcitonin may play in the decision making process and the need for revision of current guidelines and recommendations.
19:15
•
2722-1
•
AMS in COVID times: how important is bacterial co-infection and secondary infection in individuals with coronavirus?
>
A.
Alison
HOLMES (London)
19:35
•
2722-2
•
Antibiotic prescribing in COVID-19 patients: the state of art
>
D.
Derek
MACFADDEN (Ottawa)
19:55
•
2722-3
•
AMS in COVID times: role for biomarkers/rapid diagnostics to reduce inappropriate use
>
L.
Larissa
MAY (Sacramento)
20:15
•
2722-4
•
How can we sustain and deliver effective AMS programmes during COVID?
>
B.
Benedikt
HUTTNER (Geneva)
20:35
•
2722-5
•
Q&A/Discussion
|